First-in-human studies in sight, SQZ’s cell therapy tech wins over a diverse group of investors in $72M round

Having steadily built out the preclinical data to cement its cell therapy platform and sorted out the technicalities, SQZ Biotech has raised $72 million to make its first drive to the clinic. The Series C marks the biggest round by far for Boston-based SQZ … (본문 전체 8/9/2018 8:58 PM)

1 thought on “First-in-human studies in sight, SQZ’s cell therapy tech wins over a diverse group of investors in $72M round”

Leave a Comment